Impact of Brokerage Rating on PDL BioPharma, Inc.(PDLI)

Many PDL BioPharma, Inc.(PDLI) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. PDL BioPharma Inc was Resumed by Piper Jaffray to Overweight on Dec 22, 2016.

Company has reported several Insider transactions to the SEC, on Aug 10, 2016, Peter S Garcia (CFO) purchased 10,000 shares at 2.99 per share price.On Dec 7, 2015, Steffen Pietzke (Controller and CAO) purchased 20,590 shares at 3.64 per share price.

PDL BioPharma Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $0.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $0.02. The company had revenue of $53.60 million for the quarter, compared to analysts expectations of $50.70 million. The companys revenue was down -57.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.42 EPS.

PDL BioPharma, Inc. (NASDAQ:PDLI) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 1 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys.

PDL BioPharma, Inc. (NASDAQ:PDLI): The mean estimate for the short term price target for PDL BioPharma, Inc. (NASDAQ:PDLI) stands at $3.67 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $4 while the lower price target estimate is at $3.

PDL BioPharma, Inc. (NASDAQ:PDLI) rose 2.67% or 0.06 points on Tuesday and made its way into the gainers of the day. After trading began at $2.22 the stock was seen hitting $2.32 as a peak level and $2.22 as the lowest level. The stock ended up at $2.31. The daily volume was measured at 1,670,526 shares. The 52-week high of the share price is $3.84 and the 52-week low is $1.93. The company has a market cap of $382 million.

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.


For any feedback and suggestions contact author at

Add Comment